Description

Citozar (cytarabine) powder for solution 1000 mg. №1 vial

Ingredients

Active ingredient: Cytarabine
Inactive ingredients: mannitol, sodium hydroxide, and hydrochloric acid.

Dosage

Dosage: The dosage of Citozar (cytarabine) is individualized based on the patient’s condition, weight, and response to treatment. It is administered intravenously by a healthcare professional.

Indications

Indications: Citozar (cytarabine) is indicated for the treatment of various types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Contraindications

Contraindications: Citozar (cytarabine) is contraindicated in patients with known hypersensitivity to cytarabine or any of the inactive ingredients in the product.

Directions

Administration: Citozar (cytarabine) should only be administered by healthcare professionals experienced in the use of cytotoxic drugs. The solution should be prepared according to the manufacturer’s instructions and administered as directed.

Scientific Evidence

Cytarabine is a cornerstone in the treatment of leukemia due to its ability to inhibit DNA synthesis in rapidly dividing cells. Studies have shown that cytarabine, when used in combination with other chemotherapeutic agents, can significantly improve outcomes in patients with leukemia. Research published in the New England Journal of Medicine has demonstrated the efficacy of cytarabine in inducing remission in patients with AML.

Additional Information

Citozar (cytarabine) may cause side effects such as bone marrow suppression, nausea, vomiting, and hair loss. Regular monitoring of blood counts is essential during treatment. It is important to discuss the potential risks and benefits of treatment with your healthcare provider.

Pharmacological Effects: Cytarabine exerts its cytotoxic effects by disrupting DNA synthesis, leading to cell death. It is most effective against rapidly dividing cells, making it a crucial component in the treatment of leukemia.

Clinical Trials: Clinical trials have shown that cytarabine, when used in combination regimens, can improve overall survival rates and increase the likelihood of achieving remission in patients with leukemia. These trials have established cytarabine as a standard of care in leukemia treatment protocols.